SLEEP 2020: DAYVIGO (lemborexant) treats adult insomnia, and Phase III clinically confirms its effectiveness and safety.

Insomnia is a condition that does not go to sleep naturally.
may be difficult to fall asleep (difficult to fall asleep), or difficult to maintain a long period of deep sleep.
insomnia is usually accompanied by symptoms such as poor daytime mental health, drowsiness, irritability, or depression.
Eisai Pharmaceuticals today published the main results of clinical studies in SUNRISE 1 and SUNRISE 2 that analyzed the long-term efficacy and safety of DAYVIGO's treatment of insomniacs aged 65 and over.
results were published at the Sleep Conference 2020 (SLEEP 2020).
SunRISE 2 is an open study that assesses the safety and tolerance of patients who take pyridoxine intermittently or frequently to DAYVIGO 5mg or DAYVIGO 10mg.
In the subgroup analysis, the (subjective) sleep endpoints reported by the patient were evaluated from the sleep diary data, including the sleep episode incubation period (sSOL), defined as the estimated number of minutes from the patient trying to fall asleep to the sleep episode;
results showed that 262 of the 949 patients aged 65 and over reported a decrease in sSOL as early as the first week.
in the sixth month, the mid-level sSOL of patients in the DAYVIGO 5 mg or DAYVIGO 10 mg group was significantly different from the baseline compared to those in the placebo group.
.